Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.94M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
99.8M
-
Shares change
-
-7.82M
-
Total reported value, excl. options
-
$73.2M
-
Value change
-
-$4.98M
-
Put/Call ratio
-
0.2
-
Number of buys
-
35
-
Number of sells
-
-40
-
Price
-
$0.73
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q4 2024
116 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q4 2024.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 99.8M shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (16.9M shares), NEA Management Company, LLC (15M shares), BlackRock, Inc. (11.1M shares), VANGUARD GROUP INC (8.2M shares), ACORN CAPITAL ADVISORS, LLC (7.31M shares), ORBIMED ADVISORS LLC (7.13M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (4.94M shares), GEODE CAPITAL MANAGEMENT, LLC (3.5M shares), AXA S.A. (3.07M shares), and STATE STREET CORP (3.06M shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.